Share on LinkedInShare on LinkedIn

ARTICLE · 11 JUNE 2024

The Uniform Code For Pharmaceutical Marketing Practices, 2024 — Impact On India's Pharma Industry

Majmudar & Partners
Majmudar & Partners
Contributor
Majmudar & Partners

Majmudar & Partners

Majmudar & Partners, established in 1943, is one of India’s premier law firms representing leading...

View firm profile
Explore more from Majmudar & Partners

This article discusses the revisions made and identifies key compliances for pharmaceutical companies ("Companies") in relation to marketing their products.

IndiaCorporate/Commercial Law

The Department of Pharmaceuticals (the "DoP") recently notified the Uniform Code for Pharmaceutical Marketing Practices 2024 ("UCPMP 2024"), in supersession of the UCPMP issued in 2014 ("UCPMP 2014").

This article discusses the revisions made and identifies key compliances for pharmaceutical companies ("Companies") in relation to marketing their products.

Background

India has various laws to regulate how drugs are advertised and marketed by Companies to end-consumers, including: (i) the Drugs and Cosmetics Act, 1940, and the rules thereunder; (ii) the Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954; (iii) the Consumer Protection Act, 1986; (iv) the Advertising Standards Council of India's Code for Self-Regulation in Advertising; and (v) the Guidelines for Prevention of Misleading Advertisements and Endorsements for Misleading Advertisements, 2022.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from